Oncotype DX Breast Recurrence Score

How to interpret the Oncotype DX® test results?

For your patients with HR+, HER2-, early-stage, invasive breast cancer

The Oncotype DX Breast Recurrence Score report provides three points of clarity to aid in treatment decisions (chemotherapy, yes or no) for node-negative and node-positive, hormone receptor-positive, HER2-negative, early-stage breast cancer patients.

3 pieces of information provided by the test

1

Recurrence Score result

This number, between 0 and 100, is calculated by measuring the activity of specific genes in the breast cancer tissue. The Recurrence Score® result is used to predict the risk of the breast cancer returning at a distant site and whether chemotherapy may help reduce the risk.1,3-6

2

Distant recurrence risk at 9 yearsa

This percentage shows how likely it is that a patient’s breast cancer will come back somewhere else in the body, “distant recurrence,” within 9 years when treated with hormonal therapy alone for 5 years.1,4,5

3

Absolute chemotherapy benefita

This percentage indicates the benefit expected from adding chemotherapy to hormonal therapy in order to reduce the risk of cancer recurrence or death for the recurrence score group.3,4,6

a These results are valid in HR+, HER2-, early-stage, invasive breast cancer patients treated with 5 years of endocrine therapy.

Explore the patient reports

Breast Recurrence Score Report: Node-Negative
START REPORT GUIDE
Report Image
START REPORT GUIDE
Report Image
START REPORT GUIDE

Support Materials

Download clinician-to-patient discussion guides

Contact Us